Clinverse Introduces ClinPlan
Clinverse, Inc., provider of automated financial management technology solutions for clinical trials, announced today that it has expanded its suite of products with the addition of ClinPlan™, purpose-built software for clinical trial budget management and forecasting.
Clinverse has expanded its suite of products with the addition of ClinPlan™, software for clinical trial budget management and forecasting. ClinPlan provides clients with the ability to consolidate budgets from the variety of vendors and sources that contribute to the total trial expense. The solution also imports site activation data and schedule of assessments and related expenses to allow the cost over time to be evaluated and reevaluated using actual data once the trial begins.
Read the full release here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.
